MX2007000606A - Arilidenos para el tratamiento de enfermedades mediadas por receptor alfa relacionado con estrogeno. - Google Patents
Arilidenos para el tratamiento de enfermedades mediadas por receptor alfa relacionado con estrogeno.Info
- Publication number
- MX2007000606A MX2007000606A MX2007000606A MX2007000606A MX2007000606A MX 2007000606 A MX2007000606 A MX 2007000606A MX 2007000606 A MX2007000606 A MX 2007000606A MX 2007000606 A MX2007000606 A MX 2007000606A MX 2007000606 A MX2007000606 A MX 2007000606A
- Authority
- MX
- Mexico
- Prior art keywords
- arylidenes
- treatment
- related receptor
- mediated diseases
- estrogen related
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 108091008559 estrogen-related receptor alpha Proteins 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 150000004646 arylidenes Chemical class 0.000 title 1
- 208000035475 disorder Diseases 0.000 abstract 1
- -1 heterocyclic arylidene aryl ether compounds Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen metodos terapeuticos de uso de ciertos compuestos de aril eter de arilidenos heterociclicos para el tratamiento de enfermedades o trastornos mediados a traves de la modulacion del receptor alfa relacionado con estrogenos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58785004P | 2004-07-14 | 2004-07-14 | |
PCT/US2005/024703 WO2006019741A1 (en) | 2004-07-14 | 2005-07-08 | Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007000606A true MX2007000606A (es) | 2007-06-25 |
Family
ID=35045035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007000606A MX2007000606A (es) | 2004-07-14 | 2005-07-08 | Arilidenos para el tratamiento de enfermedades mediadas por receptor alfa relacionado con estrogeno. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20060014812A1 (es) |
EP (1) | EP1781271A1 (es) |
JP (1) | JP2008506691A (es) |
KR (1) | KR20070041560A (es) |
CN (1) | CN101014327A (es) |
AU (1) | AU2005275279A1 (es) |
BR (1) | BRPI0513367A (es) |
CA (1) | CA2573761A1 (es) |
EA (1) | EA200700262A1 (es) |
IL (1) | IL180657A0 (es) |
MX (1) | MX2007000606A (es) |
NO (1) | NO20070855L (es) |
WO (1) | WO2006019741A1 (es) |
ZA (1) | ZA200701277B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2583271C (en) * | 2004-10-22 | 2014-05-20 | Exelixis, Inc. | Benzylthiazolone inhibitors of estrogen-related receptors (err) |
CN103251579B (zh) | 2006-08-24 | 2016-12-28 | 田纳西大学研究基金会 | 取代的n-酰基苯胺及其使用方法 |
WO2008105326A1 (ja) * | 2007-02-28 | 2008-09-04 | Ohara Chemical Industries, Ltd. | 2-イミノ-4-チアゾリジノン誘導体及び2,4-チアゾリジンジオン誘導体の製造方法 |
NZ579372A (en) * | 2007-03-07 | 2012-02-24 | Janssen Pharmaceutica Nv | Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
WO2008109737A1 (en) * | 2007-03-07 | 2008-09-12 | Janssen Pharmaceutica N.V. | Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators |
PT2132188E (pt) | 2007-03-07 | 2012-02-13 | Janssen Pharmaceutica Nv | Tiazolidinedionas n-alquiladas fenoxi substituídas como moduladores de receptores-alfa de estrogénio |
JPWO2011016501A1 (ja) * | 2009-08-04 | 2013-01-10 | 武田薬品工業株式会社 | 癌の予防ないし治療薬 |
WO2011019558A1 (en) * | 2009-08-11 | 2011-02-17 | Janssen Pharmaceutica Nv | Methods to measure dissociation rates for ligands that form reversible covalent bonds |
WO2011019556A1 (en) | 2009-08-11 | 2011-02-17 | Janssen Pharmaceutica Nv | CO-CRYSTALLIZATION OF ERR-A α WITH A LIGAND THAT FORMS A REVERSIBLE CONVALENT BOND |
EP2488027A4 (en) * | 2009-10-09 | 2013-04-17 | Univ Ohio State Res Found | THIAZOLIDINDIONENERGIERESTRIKTIONSMIMETIKA |
CA2784753A1 (en) * | 2009-12-18 | 2011-06-23 | Janssen Pharmaceutica Nv | Substituted aminothiazolone indazoles as estrogen related receptor-.alpha. modulators |
AU2011218268A1 (en) * | 2010-02-17 | 2012-09-06 | Janssen Pharmaceutica Nv | Aminothiazolones as estrogen related receptor-alpha modulators |
CA2789757A1 (en) * | 2010-02-17 | 2011-08-25 | Janssen Pharmaceutica Nv | Aminothiazolones as estrogen related receptor-alpha modulators |
WO2011149841A1 (en) | 2010-05-25 | 2011-12-01 | Janssen Pharmaceutica Nv | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS |
US9295754B2 (en) | 2011-02-24 | 2016-03-29 | Emory University | Noggin inhibitory compositions for ossification and methods related thereto |
WO2013018929A1 (en) | 2011-08-04 | 2013-02-07 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
PT2872482T (pt) | 2012-07-13 | 2020-09-22 | Oncternal Therapeutics Inc | Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
CN108611409B (zh) * | 2018-03-30 | 2020-07-17 | 青岛泱深生物医药有限公司 | 用于诊治类风湿性关节炎和骨关节炎的生物标志物 |
KR102243465B1 (ko) * | 2019-08-05 | 2021-04-22 | 리퓨어생명과학 주식회사 | 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물 |
KR102301274B1 (ko) * | 2019-08-05 | 2021-09-14 | 리퓨어생명과학 주식회사 | 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326770A (en) * | 1992-07-17 | 1994-07-05 | The Du Pont Merck Pharmaceutical Company | Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals |
DE4318550A1 (de) * | 1993-06-04 | 1994-12-08 | Boehringer Mannheim Gmbh | Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
US6251928B1 (en) * | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
GB9418762D0 (en) * | 1994-09-16 | 1994-11-02 | Bayer Ag | Use of substituted cyclopentane-DI-and-triones |
JP3783810B2 (ja) * | 1997-01-14 | 2006-06-07 | 第一製薬株式会社 | 新規ベンゾフラノン誘導体及びその製造方法 |
US7541141B2 (en) * | 1997-02-27 | 2009-06-02 | Wisconsin Alumni Research Foundation | Method of using estrogen-related receptor alpha (ERRα) status to determine prognosis, treatment strategy and predisposition to breast cancer, and method of using ERRα as a therapeutic target for the treatment of breast cancer |
WO2000018746A1 (en) * | 1998-09-30 | 2000-04-06 | Roche Diagnostics Gmbh | Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders |
US7407978B2 (en) * | 1999-04-06 | 2008-08-05 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
JP2001031660A (ja) * | 1999-07-14 | 2001-02-06 | Iyaku Bunshi Sekkei Kenkyusho:Kk | 甲状腺ホルモン様作用物質 |
US6525093B1 (en) * | 1999-11-08 | 2003-02-25 | Calyx Therapeutics Inc. | Compounds to treat diabetes and associated conditions |
WO2002080888A2 (en) * | 2001-04-04 | 2002-10-17 | Edith Bonnelye | Estrogen receptor-related receptor alpha (err) agonist for inducing cartilage formation |
CA2441274A1 (en) * | 2001-04-18 | 2002-10-24 | Pharmacia Italia S.P.A. | Aurones as telomerase inhibitors |
AU2003225668A1 (en) * | 2002-03-01 | 2003-09-16 | Pintex Pharmaceutical, Inc. | Pin1-modulating compounds and methods of use thereof |
US6620838B1 (en) * | 2002-04-19 | 2003-09-16 | Signal Pharmaceuticals, Inc. | Benzopyrazone compounds, compositions thereof, and methods of treatment therewith |
EP1398029A1 (en) * | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
-
2005
- 2005-07-08 CN CNA2005800303249A patent/CN101014327A/zh active Pending
- 2005-07-08 EP EP05769266A patent/EP1781271A1/en not_active Withdrawn
- 2005-07-08 KR KR1020077002815A patent/KR20070041560A/ko not_active Application Discontinuation
- 2005-07-08 BR BRPI0513367-0A patent/BRPI0513367A/pt not_active IP Right Cessation
- 2005-07-08 US US11/177,716 patent/US20060014812A1/en not_active Abandoned
- 2005-07-08 AU AU2005275279A patent/AU2005275279A1/en not_active Abandoned
- 2005-07-08 JP JP2007521573A patent/JP2008506691A/ja not_active Withdrawn
- 2005-07-08 WO PCT/US2005/024703 patent/WO2006019741A1/en active Application Filing
- 2005-07-08 MX MX2007000606A patent/MX2007000606A/es not_active Application Discontinuation
- 2005-07-08 CA CA002573761A patent/CA2573761A1/en not_active Abandoned
- 2005-07-08 EA EA200700262A patent/EA200700262A1/ru unknown
-
2007
- 2007-01-11 IL IL180657A patent/IL180657A0/en unknown
- 2007-02-13 ZA ZA200701277A patent/ZA200701277B/xx unknown
- 2007-02-14 NO NO20070855A patent/NO20070855L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2008506691A (ja) | 2008-03-06 |
CN101014327A (zh) | 2007-08-08 |
EP1781271A1 (en) | 2007-05-09 |
CA2573761A1 (en) | 2006-02-23 |
BRPI0513367A (pt) | 2008-05-06 |
IL180657A0 (en) | 2008-03-20 |
ZA200701277B (en) | 2008-09-25 |
KR20070041560A (ko) | 2007-04-18 |
WO2006019741A1 (en) | 2006-02-23 |
AU2005275279A1 (en) | 2006-02-23 |
US20060014812A1 (en) | 2006-01-19 |
NO20070855L (no) | 2007-03-19 |
EA200700262A1 (ru) | 2007-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007000606A (es) | Arilidenos para el tratamiento de enfermedades mediadas por receptor alfa relacionado con estrogeno. | |
NL301145I2 (nl) | Tirbanibulin | |
NO2017019I2 (no) | Enzalutamid eller et farmasøytisk akseptabelt salt derav | |
EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
DK1656346T3 (da) | 1,2,3,4-tetrasubstituerede indol til behandling af luftvejssygdomme | |
DE602005009748D1 (de) | 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors | |
DK1812110T3 (da) | Apparat til behandling af dermatologiske lidelser | |
EA200501430A1 (ru) | Лиганды каннабиноидных рецепторов и их применение | |
MY169308A (en) | Treatment of tnf? related disorders | |
DE60309909D1 (de) | Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen | |
MX2010003658A (es) | Sistema quirurgico no invasivo basado en fotones que incluye control celular automatico y erradicacacion por control de proalimentacion pre-calculada mas control de retroalimentacion de imagen para suministro enfocado de energia. | |
NO20071272L (no) | Modulatorer av muskarine reseptorer. | |
DK2004181T6 (da) | Androgen receptormodulator til behandling af prostatacancer og androgen receptor-associerede sygdomme | |
EA200971077A1 (ru) | Гетероциклические модуляторы киназы | |
DE602005007623D1 (de) | Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine | |
MY145305A (en) | Cyclopropyl amines as modulators of the histamine h3 receptor | |
EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
DE502004010131D1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
DK1325011T3 (da) | Fremgangsmåder og forbindelser til behandling af proliferative sygdomme | |
DK1499730T3 (da) | Immunokonjugater til behandling af tumorer | |
NO20073369L (no) | Modulatorer av muskarinreseptorer | |
WO2005089294A3 (en) | Synthesis of indenoisoquinoliniums and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |